Financial Analysts Roundtable Part II: Changes On Capitol Hill, FDA’s Risk Threshold And The Future Of The Cholesterol Market

The following excerpts are from a conversation "The Pink Sheet" had with three large cap pharmaceutical analysts, Prudential's Tim Anderson, Goldman Sachs' Jim Kelly and Morgan Stanley's Jami Rubin, concerning the outlook for the drug industry in 2007. 1Kelly and 2Rubin provided "The Pink Sheet" with extensive disclosure statements, which can be accessed by visiting 3www.ThePinkSheet.com. The 4first part of the series, which covered Medicare Part D, big pharma diversification, and the outlook for M&A, appeared in the Feb. 5 issue of "The Pink Sheet."